Novartis plans to seek quick regulatory approvals from health authorities for the drug, known as GanLum, which would be the ...

Swiss pharmaceutical giant Novartis has unveiled a next-generation malaria treatment that not only demonstrates a 97% cure ...

Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose ...

In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

Scientists have created the first new anti- malaria drug in a quarter of a century to combat resistance to existing ...

An experimental drug was effective against malaria in a new study, potentially offering a much-needed buffer against the ...

Malaria is a mosquito-borne parasitic disease that can cause serious illness and death. It is caused by a parasite called Plasmodium and is transmitted through the bite of infected female Anopheles ...

Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of thousands of ...

Swiss medical authorities have approved the first drug suitable to treat malaria in babies and very young children. Eight African countries that participated in clinical trials are now poised to ...

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including older children. Dr.